I recommend avoiding shares of Osiris Therapeutics (OSIR). I believe the stock is meaningfully over-valued at this price, and I see potential clinical failures, the dissolution of the development...(read more
Osiris Therapeutics, Inc. (NASDAQ: OSIR) announced today its results for the third quarter of fiscal 2010.
Net income for the third quarter of 2010 was $4.5 million compared to a loss from continuing operations of $6.8 million in the...(read more
Osiris Therapeutics (OSIR) reported a net loss of a cent in the fourth quarter of 2009, well below the Zacks Consensus Estimate of a net income of 23 cents per share. However, net loss...(read more